Cancer Discovery Solutions
Hereditary risk tests are medical tests that look for different known hereditary genetic mutations. These types of tests, which are also called predictive genetic tests, are usually recommended when there are certain hereditary cancers in a family and the presence of a genetic mutation is presumed to be a possible cause of them.
In order to contribute to the detection of highly hereditary cancer types, BIOPROGNOS markets a series of hereditary risk tests for Illumina ―the leading company in Simple Nucleotide Polymorphism (SNP) genotyping―, based on a simple analysis of saliva and seeking to position itself as the first line in the detection aid:
For years, biopsy and imaging have been at the forefront of cancer treatment, providing important insights about cancer, especially when it comes to detection.
In this way, several imaging tests were developed, mainly from two big groups:
But these procedures are inherently limited. The added risk and stress associated with biopsy can be hard on patients. And for those with advanced or inaccessible cancers, biopsy and imaging may not be an option. Scans may be less invasive, but do not provide critical molecular information. These procedures add significant costs over the course of treatment.
Finally, and most importantly, most of these imaging procedures emit radiation.
In this way, BIOPROGNOS has developed its own technology called “Multiple Biomarkers Disease Activity Algorithms” (MBDAAs) in order to create a Non-Invasive first-line for diagnosis: